Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection

Journal of Rheumatology

Volumn 32, Issue 3, 2005, Pages 489-493

  Lienesch, Douglas ^a,c   Morris, Robert ^b   Metzger, Allan ^b   Debuys, Paige ^a   Sherman, Kenneth ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Cyclic citrullinated peptide; Hepatitis C virus; Rheumatoid factor

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHEUMATOID FACTOR;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NONARTICULAR RHEUMATISM; PRIORITY JOURNAL; REGRESSION ANALYSIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS;

EID: 15044358143     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Alter MJ. Hepatitis C virus infection in the United States. J Hepatol 1999;31 Suppl 1:88-91.
2. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989;16:427-41.
3. Lovy MR, Starkebaum G, Uberoi S. Hepatitis C infection presenting with rheumatic manifestations: a mimic of rheumatoid arthritis. J Rheumatol 1996;23:979-83.
4. Zuckerman E, Keren D, Rozenbaum M, et al. Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha. Clin Exp Rheumatol 2000;18:579-84.
5. Rivera J, Garcia-Monforte A, Pineda A, Millan Nunez-Cortes J. Arthritis in patients with chronic hepatitis C virus infection. J Rheumatol 1999;26:420-4.
6. Hsu FC, Starkebaum G, Boyko EJ, Dominitz JA. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. J Rheumatol 2003;30:455-8.
7. Ueno Y, Kinoshita R, Kishimoto I, Okamoto S. Polyarthritis associated with hepatitis C virus infection. Br J Rheumatol 1994;33:289-91.
8. Ramos-Casals M, Trejo O, Garcia-Carrasco M, Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology Oxford 2003;42:818-28.
9. Shmerling RH, Delbanco TL. How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value. Arch Intern Med 1992;152:2417-20.
10. Romero Portales M, De Diego Lorenzo A, Rivera J, et al. Rheumatologic and autoimmune manifestations in patients with chronic hepatitis C virus infection. Rev Esp Enferm Dig 1997;89:591-8.
11. Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998;28:107-13.
12. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med 1995;122:169-73.
13. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613-9.
14. Saraux A, Berthelot JM, Chales G, et al. Value of laboratory tests in early prediction of rheumatoid arthritis. Arthritis Rheum 2002;47:155-65.
15. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology Oxford 2002;41:809-14.
16. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
17. Goldbach-Mansky R, Lee J, McCoy A, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.
18. Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.
19. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt R, De Koning M, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30:1691-5.
20. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
21. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
22. Zeng X, Ai M, Tian X, et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003;30:1451-5.
23. Fadda P, La Civita L, Zignego AL, Ferri C. [Hepatitis C virus infection and arthritis. A clinico-serological investigation of arthritis in patients with or without cryoglobulinemic syndrome]. Reumatismo 2002;54:316-23.
24. Nocente R, Ceccanti M, Bertazzoni G, Cammarota G, Silveri NG, Gasbarrini G. HCV infection and extrahepatic manifestations. Hepatogastroenterology 2003;50:1149-54.
25. Medhekar S, Nutt A, Raufman JP, Jasin HE. Effect of interferon a-2b and ribavirin treatment on hepatitis C-associated cryoglobulinemia and rheumatoid factor: comment on the article by Vassilopoulos and Calabrese [letter]. Arthritis Rheum 2003;48:580-1.
26. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82.
27. Vencovsky J, Machacek S, Sedova L, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.
28. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology Oxford 2003;42:677-80.
29. Meyer O, Labarre C, Dougados M, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
30. Jonsson T, Steinsson K, Jonsson H, Geirsson AJ, Thorsteinsson J, Valdimarsson H. Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Rheumatol Int 1998;18:119-22.
31. Pai S, Pai L, Birkenfeldt R. Correlation of serum IgA rheumatoid factor levels with disease severity in rheumatoid arthritis. Scand J Rheumatol 1998;27:252-6.
32. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
33. Schott P, Hartmann H, Ramadori G. Hepatitis C virus-associated mixed cryoglobulinemia. Clinical manifestations, histopathological changes, mechanisms of cryoprecipitation and options of treatment. Histol Histopathol 2001;16:1275-85.
34. Sasso EH. The rheumatoid factor response in the etiology of mixed cryoglobulins associated with hepatitis C virus infection. Ann Med Interne Paris 2000;151:30-40.